Compare ACADIA Pharmaceuticals Inc. (ACAD) vs FMC Corp (FMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs FMC Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while FMC Corp trades at $10.96 (market cap $1.45B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 3.1× FMC Corp's market cap, and FMC Corp pays a 2.76% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | FMC | |
|---|---|---|
Market Cap | $4.49B | $1.45B |
Sector | Health | Basic Materials |
52-Week High | $28.06 | $43.90 |
52-Week Low | $20.06 | $10.80 |
Enterprise Value | $3.69B | $5.59B |
Dividend Yield | — | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
FMC Corporation trades at $11.59, up 2.11% today, but remains in a bearish technical trend. The company reported a net loss of -$2.24 billion in 2025 with negative margins, though recent strategic moves include a $400 million minority investment from Tessenderlo Group and asset sales to reduce debt. Analyst consensus is mixed with a $17.00 price target, suggesting potential upside from current levels.
The outlook hinges on successful debt reduction and operational turnaround. Investment opportunity exists if cost-cutting and partnerships restore profitability, but risks include persistent revenue declines, high leverage, and competitive pressures in the agricultural sciences sector. Execution on strategic initiatives is critical for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →
